SEL 313
Alternative Names: AAV-hOTC; SEL-313Latest Information Update: 05 Dec 2023
Price :
$50 *
At a glance
- Originator Selecta Biosciences
- Developer Cartesian Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Inborn urea cycle disorders
Most Recent Events
- 12 Aug 2021 Selecta Biosciences plans to file a clinical trial application (CTA) for Inborn urea cycle disorders in 2022
- 12 Aug 2021 Selecta Biosciences plans to file IND for Inborn urea cycle disorders in 2022
- 15 Mar 2021 Selecta Biosciences submitted pediatric investigation plan to European Medicines Agency